SF方案治疗肝硬化的疗效观察

目的：观察SF方案对代偿性乙型肝炎肝硬化患者的治疗作用。方法：代偿性乙肝肝硬化患者63例，分为治疗组33例，对照组30例。治疗组采用SF方案进行治疗，对照组采用常规护肝疗法，疗程为9～12个月，定期监测肝功能指标变化。结果：SF方案对肝硬化有较好的疗效，一是肝脏炎症反应减轻，肝功能恢复，血清ALT、AST、TBiL经治疗后治疗组均显著低于治疗前和同期对照组；二是阻止肝纤维化进展，肝纤维化指标明显好转；三是免疫功能得以改善，外周血CD4／CD8淋巴细胞比值回升，补体C3水平上升；四是抗病毒效果显著，HBVDNA阴转率达54．5％。结论：SF方案有显著改善患者肝功能，恢复患者免疫功能，抑制病毒增殖的作用，可扩大样本量进一步研究。

Observation of therapeutic effect of SF program for liver cirrhosis

Objective： To observe therapeutic effect of SF program for compensatory HBV-related liver cirrhosis. Methods： Compensatory Hepatitis B patients with liver cirrhosis are 63 cases, 33 cases divided into treatment group, other 30 cases of the control group. Treatment group applies SF programs for 9 to 12 months and control group treats with routine protective Liver measures, and liver function changes are periodically monitored. Results： SF program to liver cirrhosis has a better efficacy, first reducing liver inflammation and improving liver function, and serum aminotransferase, Aspartate aminotransferase and Total bilirubin of treatment group after treatment are significantly lower than before treatment and the same period control group. The second is to halt the progress of hepatic fibrosis, hepatic fibrosis improved significantly; The third is to improve immune function, rebound peripheral blood lymphocyte CD4/CD8 ratio and increase complement C3 level. The forth is significant antiviral effect, and HBV DNA conversion rate is 54.5 percent. Conclusion： SF program has significantly improved liver function, restore immune function and suppress virus proliferation in compensatory hepatitis B patients with liver cirrhosis. An expanded sample size is helpful to further study.